Pivotal readout
BMS reports 56-week SCOUT-HCM data for mavacamten in adolescents with obstructive HCM
In the phase 3 SCOUT-HCM study of teenagers with symptomatic obstructive hypertrophic cardiomyopathy, those on mavacamten from the start saw the provoked outflow gradient drop by 48.1 mmHg on average. No patient's ejection fraction fell below 50%. The pediatric use is approved in the US but not in China, and more data are due at the AHA meeting.
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.